Biocon appoints McKinsey for effective organisation structure

13 Feb 2013 Evaluate

In a bid to achieve ambitious sales target of $1 billion by FY2018, Biocon has hired the services of global consulting giant McKinsey to create a new structure. McKinsey is advising Biocon on an effective and scalable organisation structure to deliver on our ambitious and differentiated growth strategy

At present, the company is focusing on five key business verticals - small molecules comprising complex APIs (active pharmaceutical ingredients), biosimilars including affordable insulins and MAbs (monoclonal antibodies), novel molecules including biologicals for diabetes and autoimmune diseases, and value added generics and branded formulations - in addition to integrated research services through its subsidiary Syngene.

On the consolidated basis, the company reported 8.14% rise in its net profit at Rs 91.76 crore for the third quarter ended December 31, 2012 as compared to Rs 84.85 crore for the same quarter in the previous year. Total income of the company increased by 23.14% at Rs 659.65 crore for quarter under review as compared to Rs 535.69 crore for the quarter ended December 31, 2011. 

Biocon Share Price

392.80 4.55 (1.17%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×